Our vaccine platform is based on Toll-like Receptor (TLR) technology, which dramatically improves vaccine immunogenicity and efficacy. This technology involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production. VaxInnate’s vaccines focus on infectious diseases, including seasonal and pandemic flu, dengue and respiratory syncytial virus (RSV).
Most current vaccine manufacturing is based on growing virus in live fertilized chicken eggs. In a laborious process, the virus is then harvested, purified and processed to recover viral antigens. Egg-based systems take six to nine months to manufacture and release a year’s batch of vaccine, making it difficult to predict demand or respond quickly to public health emergencies. Mammalian cell-culture manufacturing systems for influenza vaccine, while offering several advantages, are still costly and time consuming.
VaxInnate’s fusion vaccine is efficiently and economically manufactured in bacteria. The technology for producing large quantities of proteins in bacteria has been practiced for over two decades, and many currently available protein-based drugs are manufactured in this way. The method involves the insertion of a circular DNA “vector” coding for the flagellin-antigen fusion product into bacteria. The DNA directs the synthesis of the fusion product in the bacteria that is then purified as soluble recombinant protein using simple biotechnology processes. Applied to influenza vaccines, bacteria-based production avoids traditional egg or cell culture-based manufacturing, lowers the cost of goods of the final product and establishes a more rapidly scalable manufacturing process. In addition, a bacteria-based manufacturing process avoids the risk that an avian flu pandemic will destroy egg-laying flocks.